Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
August 19, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s...
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
August 15, 2022 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second...
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
August 10, 2022 12:46 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card
August 03, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s...
Catalyst Biosciences Publishes New Investor Presentation
August 01, 2022 08:30 ET
|
Catalyst Biosciences, Inc.
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an...
Catalyst Biosciences Announces Support from Largest Single Stockholder
August 01, 2022 07:30 ET
|
Catalyst Biosciences, Inc.
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the...
Catalyst Biosciences Sends Letter to Stockholders
July 19, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior...
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
July 06, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and...
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
June 29, 2022 08:00 ET
|
Catalyst Biosciences, Inc.
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set...
Catalyst Biosciences Sells Complement Portfolio for $60 Million
May 23, 2022 08:30 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex...